How structural alignment across clinical research, development, manufacturing, and supply changes how programs progress
Drug development has long been organized around distributed execution. Clinical research, development, manufacturing, and supply operate within separate structures, with alignment rebuilt at each transition.
That model is becoming harder to sustain.
As programs expand across modalities, regions, and regulatory environments, each transition introduces friction—requiring technical context to be revalidated, documentation reconciled, and decisions re-established. The impact is cumulative, affecting timing, cost, and continuity as programs progress.
In this environment, development performance is shaped less by individual activities and more by how those activities are aligned across the lifecycle.
This whitepaper examines how coordinated governance and integrated execution are structured within Thermo Fisher Scientific to support continuity across clinical research, development, manufacturing, and supply.
The paper focuses on three structural elements:
As development programs span more functions, geographies, and regulatory environments, the way activities are coordinated increasingly determines whether progress is sustained or disrupted.
Explore how coordinated development is applied in practice and how it supports continuity, timing predictability, and program progression across clinical research, development, manufacturing, and supply.